Results 11 to 20 of about 17,785 (168)
Therapeutic potential of targeting mirnas to prostate cancer tumors: using psma as an active target
Molecular & Cellular Oncology, 2022 Prostate cancer (PC) is a commonly diagnosed malignancy in men and is associated with high mortality rates. Current treatments for PC include surgery, chemotherapy, and radiation therapy. However, recent advances in targeted delivery systems have yielded
Amir Yarahmadi +3 more
doaj +1 more source
Radiotheranostics is here to help [PDF]
Digital Diagnostics, 2021 The COVID-19 pandemic did not diminish interest in radiotheranostics. However, the demand for visualization of pathological processes using cross-sectional and hybrid imaging (CT, MRI, SPECT, and PET) is increased.
Rumyantsev O. Rumyantsev
doaj +1 more source
Current Oncology, 2023 Theranostics (therapy + diagnosis) targeting prostate-specific membrane antigen (PSMA) is an emerging therapeutic modality that could alter treatment strategies for prostate cancer.
Seiji Hoshi +11 more
doaj +1 more source
Frontiers in Oncology, 2022 PurposeHigh-grade gliomas (HGG) are still associated with a dismal prognosis. Prostate specific membrane antigen (PSMA) is discussed as a theranostic target for PSMA-directed radioligand therapy ([177Lu]Lu-PSMA RLT). Here, we report on the correlation of
Peter Truckenmueller +13 more
doaj +1 more source
Precision low-dose brachytherapy of prostate cancer under PSMA-receptor molecular visualization [PDF]
Digital Diagnostics, 2023 Brachytherapy with implantation of micro sources based on isotope 125I is a preferred treatment for localized prostate cancer without signs of germination of the gland capsule and in the absence of signs of metastases (stage cT1-T23aN0M0).
Pavel V. Sviridov +7 more
doaj +1 more source
Targeted Radiotherapeutics from 'Bench-to-Bedside'
CHIMIA, 2020 he concept of targeted radionuclide therapy (TRT) is the accurate and efficient delivery of radiation to disseminated cancer lesions while minimizing damage to healthy tissue and organs.
Cristina Müller +4 more
doaj +1 more source
An Albumin-Binding PSMA Ligand with Higher Tumor Accumulation for PET Imaging of Prostate Cancer
Pharmaceuticals, 2022 Prostate-specific membrane antigen (PSMA) is an ideal target for the diagnosis and treatment of prostate cancer. Due to the short half-life in blood, small molecules/peptides are rapidly cleared by the circulatory system. Prolonging the half-life of PSMA
Ya’nan Ren +6 more
doaj +1 more source
Gastro Hep Advances, 2022 Background and Aims: Radiolabeled short peptide ligands targeting prostate-specific membrane antigen (PSMA) were developed initially for imaging and treatment of prostate cancers.
Olga Sergeeva +14 more
doaj +1 more source
Scientific Reports, 2022 A wide variety of 18F-labeled PSMA-targeting PET radiotracers have been developed, including [18F]AlF-PSMA-11. As there is only limited data on the comparison with other 18F-labeled PSMA PET tracers, a comparative preclinical study between [18F]AlF-PSMA ...
Sarah Piron +8 more
doaj +1 more source
68Ga–Prostate-Specific Membrane Antigen: A Potential Radiopharmaceutical in PET/CT To detect primary Cholangiocarcinoma [PDF]
Asia Oceania Journal of Nuclear Medicine and Biology, 2020 68Ga Prostate-specific membrane antigen (PSMA) is an increasingly popular radiopharmaceutical tracer in prostate cancer and is becoming increasingly researched in other cancers such as breast cancer, renal cell carcinoma, glioblastoma multiforme, among ...
Rita Chahinian +5 more
doaj +1 more source